The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017)
Primary central nervous system (CNS) tumours are heterogeneous, with different treatment pathways and prognoses depending on their histological and molecular classification. Due to their anatomical location, all CNS tumours, regardless of malignancy, can be debilitating. We used vital statistics lin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/4/329 |
| _version_ | 1797605760855703552 |
|---|---|
| author | Emily V. Walker Yiling Zhou Yifan Wu Jiaqi Liu Seth A. Climans Faith G. Davis Yan Yuan |
| author_facet | Emily V. Walker Yiling Zhou Yifan Wu Jiaqi Liu Seth A. Climans Faith G. Davis Yan Yuan |
| author_sort | Emily V. Walker |
| collection | DOAJ |
| description | Primary central nervous system (CNS) tumours are heterogeneous, with different treatment pathways and prognoses depending on their histological and molecular classification. Due to their anatomical location, all CNS tumours, regardless of malignancy, can be debilitating. We used vital statistics linked to Canadian Cancer Registry data to estimate the age-standardized incidence rates (ASIR), Kaplan–Meier survival rates (SR), and limited-duration prevalence proportions (PP) of 25 histology-specific CNS tumour groups that were classified based on site and histology. During 2010–2017, 45,115 patients were diagnosed with 47,085 primary CNS tumours, of which 19.0% were unclassified. The average annual ASIR was 21.48/100,000 person-years and did not vary by sex. The ASIR increased with age, particularly for meningioma, unclassified tumours, and glioblastoma. The eight-year PP was 102.1/100,000 persons (index date 1 January 2018). The most common histology was meningioma (ASIR: 5.19; PP: 31.6). The overall five-year SR among 51,310 patients diagnosed during 2008–2017 was 57.2% (95% CI: 56.8–57.7%). SRs varied by tumour behaviour, histology, and patient age, with the lowest SR among glioblastoma patients (5-year SRs ranged from 1.3–25.7%). For non-malignant tumours, the 5-year SRs ranged from 37.4–100%. We provide the most up-to-date histology-specific surveillance estimates for primary CNS tumours in Canada. |
| first_indexed | 2024-03-11T05:05:39Z |
| format | Article |
| id | doaj.art-0d7dd66aa2f045fb8528fb67eafc7367 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T05:05:39Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-0d7dd66aa2f045fb8528fb67eafc73672023-11-17T18:53:13ZengMDPI AGCurrent Oncology1198-00521718-77292023-04-013044311432810.3390/curroncol30040329The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017)Emily V. Walker0Yiling Zhou1Yifan Wu2Jiaqi Liu3Seth A. Climans4Faith G. Davis5Yan Yuan6School of Public Health, University of Alberta, Edmonton, AB T6G 1C9, CanadaSchool of Public Health, University of Alberta, Edmonton, AB T6G 1C9, CanadaSchool of Public Health, University of Alberta, Edmonton, AB T6G 1C9, CanadaSchool of Public Health, University of Alberta, Edmonton, AB T6G 1C9, CanadaDepartment of Oncology, Western University, London, ON N6A 5W9, CanadaSchool of Public Health, University of Alberta, Edmonton, AB T6G 1C9, CanadaSchool of Public Health, University of Alberta, Edmonton, AB T6G 1C9, CanadaPrimary central nervous system (CNS) tumours are heterogeneous, with different treatment pathways and prognoses depending on their histological and molecular classification. Due to their anatomical location, all CNS tumours, regardless of malignancy, can be debilitating. We used vital statistics linked to Canadian Cancer Registry data to estimate the age-standardized incidence rates (ASIR), Kaplan–Meier survival rates (SR), and limited-duration prevalence proportions (PP) of 25 histology-specific CNS tumour groups that were classified based on site and histology. During 2010–2017, 45,115 patients were diagnosed with 47,085 primary CNS tumours, of which 19.0% were unclassified. The average annual ASIR was 21.48/100,000 person-years and did not vary by sex. The ASIR increased with age, particularly for meningioma, unclassified tumours, and glioblastoma. The eight-year PP was 102.1/100,000 persons (index date 1 January 2018). The most common histology was meningioma (ASIR: 5.19; PP: 31.6). The overall five-year SR among 51,310 patients diagnosed during 2008–2017 was 57.2% (95% CI: 56.8–57.7%). SRs varied by tumour behaviour, histology, and patient age, with the lowest SR among glioblastoma patients (5-year SRs ranged from 1.3–25.7%). For non-malignant tumours, the 5-year SRs ranged from 37.4–100%. We provide the most up-to-date histology-specific surveillance estimates for primary CNS tumours in Canada.https://www.mdpi.com/1718-7729/30/4/329brain tumourssurveillancefive-year survival rate10-year survival curveprevalence rateincidence rate |
| spellingShingle | Emily V. Walker Yiling Zhou Yifan Wu Jiaqi Liu Seth A. Climans Faith G. Davis Yan Yuan The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017) Current Oncology brain tumours surveillance five-year survival rate 10-year survival curve prevalence rate incidence rate |
| title | The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017) |
| title_full | The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017) |
| title_fullStr | The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017) |
| title_full_unstemmed | The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017) |
| title_short | The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017) |
| title_sort | incidence and prevalence of primary central nervous system cns tumours in canada 2010 2017 and the survival of patients diagnosed with cns tumours 2008 2017 |
| topic | brain tumours surveillance five-year survival rate 10-year survival curve prevalence rate incidence rate |
| url | https://www.mdpi.com/1718-7729/30/4/329 |
| work_keys_str_mv | AT emilyvwalker theincidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT yilingzhou theincidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT yifanwu theincidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT jiaqiliu theincidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT sethaclimans theincidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT faithgdavis theincidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT yanyuan theincidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT emilyvwalker incidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT yilingzhou incidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT yifanwu incidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT jiaqiliu incidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT sethaclimans incidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT faithgdavis incidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 AT yanyuan incidenceandprevalenceofprimarycentralnervoussystemcnstumoursincanada20102017andthesurvivalofpatientsdiagnosedwithcnstumours20082017 |